Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?

Basit Öğe Kaydı
dc.contributor.authorBozkurt, Oktay
dc.contributor.authorKaraca, Halit
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorDuzkopru, Yakup
dc.contributor.authorUysal, Mukremin
dc.contributor.authorBerk, Veli
dc.date.accessioned2024-04-24T17:14:47Z
dc.date.available2024-04-24T17:14:47Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: The main goal of this study was to examine whether the occurrence of hypothyroidism during sunitinib therapy in patients with metastatic renal cell carcinoma (mRCC) is associated with a better outcome. Methods: The study enrolled 81 patients with pathologically proven mRCC who were treated with sunitinib between March 2008 and June 2013. Thyroid function evaluation comprised (free-thyroxine) FT4 and thyroid-stimulating hormone (TSH) before treatment and at day 1 of each 6-week cycle. Survival analysis was performed using the Kaplan-Meier method, and the differences among the groups were determined using the log-rank test. Results: Hypothyroidism occurred in 30 (37%) of 81 patients within a median 3 months (range 1-18) of treatment initiation. There was a statistically significant correlation between the occurrence of hypothyroidism during treatment and the rate of objective remission (ORR) (hypothyroid patients vs euthyroid patients: 46.7 vs 13.7%, respectively; P = 0.001). Median progression-free survival (PFS) was 10 (95% CI 6.13-13.8) months in the euthyroid patients, and 17 (95% CI 9.33-24.6) months in the hypothyroid patients (P = 0.001). The median overall survival (OS) was 39 (95% CI 25.4-52.5) months in the hypothyroid patients and 20 (95% CI 14.7-25.2) months in the euthyroid patients (P = 0.019). Conclusions: The occurrence of hypothyroidism during treatment in patients was significantly associated with longer PFS, OS and better ORR in the current study.en_US
dc.identifier.doi10.1179/1973947815Y.0000000039
dc.identifier.endpage234en_US
dc.identifier.issn1120-009X
dc.identifier.issn1973-9478
dc.identifier.issue3en_US
dc.identifier.pmid25948423
dc.identifier.scopus2-s2.0-84978701682
dc.identifier.scopusqualityQ3
dc.identifier.startpage230en_US
dc.identifier.urihttps://doi.org/10.1179/1973947815Y.0000000039
dc.identifier.urihttps://hdl.handle.net/11468/18196
dc.identifier.volume28en_US
dc.identifier.wosWOS:000380283700015
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal of Chemotherapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHypothyroidismen_US
dc.subjectSunitiniben_US
dc.subjectPrognosisen_US
dc.subjectMetastatic Renal Cell Canceren_US
dc.titleIs sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?en_US
dc.titleIs sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu